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ATP release from erythrocytes in response to low oxygen tension requires an increase in cAMP, the level
of which is regulated by phosphodiesterase 3 (PDE3). Such release is defective in erythrocytes of humans
with type 2 diabetes (DM2). This study tested a hypothesis that direct delivery of the clinically useful
PDE3 inhibitor, cilostazol, to erythrocytes of humans with type 2 diabetes using liposomes would restore
low-oxygen tension-induced ATP release. Cilostazol was incorporated into liposomes prepared from
dimyristoylphosphatidylcholine (DMPC). Liposome-delivery of cilostazol restored ATP release from DM2
erythrocytes to levels which were not different from that released from non-cilostazol treated healthy
erythrocytes under the same conditions. There were no observed adverse effects of the liposomes on
either healthy or DM2 erythrocytes. The directed liposomal delivery of PDE inhibitors to erythrocytes
may help prevent or slow the development of peripheral vascular disease in individuals with DM2 by
restoring an important physiological controller of microvascular perfusion while minimizing side effects
associated with systemic delivery of some of these inhibitors.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Erythrocytes, in addition to carrying and delivering oxygen
(O2), have been shown to play an active role in the distribution of
local microvascular perfusion via their ability to release the potent
vasodilator, ATP. Several physiological stimuli for erythrocyte ATP
release have been identiﬁed including exposure of the cells to
prostacyclin (PGI2) analogs and low O2 tension. Indeed, low
O2-induced release of ATP has been suggested to be an important
regulator of perfusion distribution and oxygen supply in skeletal
muscle [1,2]. As such, a defect in this pathway would be expected
to result in alterations in normal physiological function. Ery-
throcytes obtained from humans with type 2 diabetes (DM2), a
disease associated with an increased incidence of peripheral vas-
cular disease, fail to release ATP in response to low O2 [3–5]. It is
reasonable to hypothesize that restoration of low O2-induced ATP
release from DM2 erythrocytes could be important for the pre-
vention and treatment of the claudication and delayed woundB.V. This is an open access article u
Pinkhassik).healing associated with this disease.
The signaling pathways for ATP release in response to exposure
to PGI2 or low O2 have been elucidated and, although the path-
ways differ in several ways, in both pathways, ATP release requires
increases in intracellular cyclic adenosine monophosphate (cAMP).
In all cells, cAMP levels are determined by the rate of synthesis by
adenylyl cyclases and degradation by phosphodiesterases (PDEs)
[6]. In the PGI2 and low O2 signaling pathways in human ery-
throcytes, the phosphodiesterase responsible for degradation of
cAMP is a pathway speciﬁc isoform of PDE3 (Fig. 1) [7].
If increases in cAMP are required for ATP release from ery-
throcytes, inhibition of the PDE that degrades that cyclic nucleo-
tide could rescue low O2-induced ATP release from DM2 ery-
throcytes [3]. Indeed, it was shown that incubation of DM2 ery-
throcytes with a selective PDE3 inhibitor (cilostazol) restored ATP
release when these cells were exposed to low O2 [3]. The im-
portance of the restoration of this physiological response to low O2
is illustrated by the ﬁnding that cilostazol also restored the ability
of DM2 erythrocytes to stimulate dilation of isolated skeletal
muscle arterioles exposed to reduced extraluminal O2, a model of
increased tissue O2 need [3].
Although such studies have provided strong support for the usender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Signaling pathways for ATP release from erythrocytes in response to pros-
tacyclin analogs (A) and low O2 tension (B). Abbreviations: AC: adenylyl cyclase;
AMP: adenosine monophosphate; ATP: adenosine 5′ triphosphate; cAMP: 3′,5′-
cyclic adenosine monophosphate; CFTR: cystic ﬁbrosis transmembrane con-
ductance regulator; Gi and Gs: the heterotrimeric G proteins, Gi and Gs, respec-
tively IPR: prostacyclin receptor; PDE3: phosphodiesterase 3; PKA: protein kinase
A; VDAC: voltage-dependent anion channel; (þ): activation.
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these drugs has been associated with the unwanted side-effects of
cardiac arrhythmias and worsening of heart failure [8]. Thus, the
use of PDE3 inhibitors in DM2 has not been widely adopted. Tar-
geted delivery of PDE3 inhibitors to erythrocytes in DM2 patients
may alleviate the side effects while providing the beneﬁts of re-
storation of ATP release in response to low oxygen. Here we report
the results of feasibility studies undertaken to develop liposomes
that could deliver PDE3 inhibitors directly to erythrocytes. This
approach could permit the use of these drugs in the treatment of
DM2-associated vascular disease while avoiding unwanted cardiac
side effects.
Liposomes have been used to encapsulate a broad range of
water-insoluble (lipophilic) or hydrophilic drugs [9–12]. Targeting
speciﬁc tissues using liposomes has been challenging, in part be-
cause liposomes interact extensively with components of blood,
including erythrocytes [13–16]. However, this challenge for lipo-
some-based delivery vehicles to tissues is a distinct advantage for
their delivery to erythrocytes. Here we show that dimyr-
istoylphosphatidylcholine (DMPC) liposomes formulated with ci-
lostazol can be taken up by erythrocytes and that liposome-de-
livered cilostazol increases the release of ATP from DM2
erythrocytes.2. Materials and methods
2.1. Preparation of liposomes
Unilamellar liposomes were prepared by the extrusion method
[17]. DMPC (20 mg) was added to a 2 mM (0.71 mg) solution of
cilostazol in a methanol/chloroform (50/50) mixture. The solvent
was evaporated using a stream of puriﬁed argon to form a lipid/
drug ﬁlm on the walls of a culture tube. The lipid ﬁlm was further
dried under vacuum for 60 min to remove traces of chloroform
and methanol. The dried ﬁlm was hydrated with 1 mL of buffer
solution (in mM: 4.7 KCl, 2.0 CaCl2, 140.5 NaCl, 1.2 MgSO4, 21.4NaHCO3, pH 7.4 at 37 °C) giving a dispersion of multilamellar ve-
sicles. The solution was then extruded through a polycarbonate
membrane with 0.1 μm pores using an Avanti Mini-Extruder
(Avanti Polar Lipids). Control liposome samples were prepared
following the same procedure but without cilostazol.
2.2. DLS analysis
Hydrodynamic diameter and polydispersity index (PDI) mea-
surements were performed on a Malvern Nano-ZS Zetasizer
(Malvern Instruments Ltd., Worcestershire, U.K.). The Helium-
Neon laser, 4 mW, operated at 633 nm, with the scatter angle ﬁxed
at 173°, and the temperature at 25 °C. 80 μL samples were placed
into disposable cuvettes without dilution (70 μL, 8.5 mm center
height Brand UV-Cuvette micro). Each data point was an average
of 10 scans.
2.3. HPLC analysis of cilostazol in liposomes
An aliquot of liposome solution (50 μL) was diluted with me-
thanol (approximately 1:20) and the solution was analyzed using
an HPLC equipped with a UV detector and a reverse-phase column
(C18, 3.9150 mm2) with methanol as the mobile phase. When
the ﬂow rate was set to 0.5 mL/min, the retention time for cilos-
tazol was approximately 1.5 min. Samples were collected during
preparation of liposomes as follows: Sample 1: a stock solution of
cilostazol in methanol (reference sample); Sample 2: a lipid mix-
ture with cilostazol in methanol; Sample 3: liposomes with ci-
lostazol immediately after hydration and extrusion; Sample 4: li-
posomes with cilostazol passed through Sephadex G50 column. All
samples showed similar results. The ﬁnding that the results from
the ﬁrst 3 steps were identical within experimental error was in-
terpreted to mean that all of the cilostazol was incorporated into
liposomes. The result for Sample 4 equaled 87–95% of the amount
measured in Sample 3. No drug was observed in the eluent after
the liposomes were collected.
2.4. LCMS determination of liposomes in erythrocytes
Phospholipids were extracted from the erythrocytes using the
method of Bligh and Dyer [18]. The chloroform–methanol layer
was removed, dried and resuspended in 1.5-mL of methanol. LCMS
analysis was used to detect the presence of cilostazol and lipids
from liposomes in the RBC membranes after incubation.
2.5. Stability of liposomes loaded with cilostazol
Samples of DMPC liposomes loaded with cilostazol were pre-
pared as described above and incubated at 4 °C. Every 24 h, an
aliquot was taken for the DLS analysis of average size and size
distribution of liposomes. DLS measurements were performed as
described above. Stability of samples was monitored for one week.
2.6. Isolation of human erythrocytes
Whole blood was obtained from healthy volunteers (n¼15) and
patients with type 2 diabetes (DM2, n¼6) by venipuncture and
collected into a syringe containing 500 units of heparin. The blood
was centrifuged at 500 g for 10 min at 4 °C. The plasma, buffy coat,
and less than 1% of the erythrocyte mass were removed by as-
piration and discarded. The packed erythrocytes were re-
suspended and washed three times in a physiological buffer con-
taining (in mM) 21.0 tris(hydroxymethyl) aminomethane, 4.7 KCl,
2.0 CaCl2, 140.5 NaCl, 1.2 MgSO4, and 5.5 glucose with 0.5% bovine
serum albumin fraction V, ﬁnal pH 7.4. Erythrocytes were prepared
on the day of use.
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Washed erythrocytes were diluted to a 20% hematocrit in the
physiological buffer. ATP was measured by the luciferin–luciferase
technique [19]. Brieﬂy, a 200 mL sample of the erythrocyte sus-
pension (0.04% hematocrit) was injected into a cuvette containing
100 mL of 10 mg/mL crude ﬁreﬂy lantern extract (Sigma, St. Louis,
MO) and 100 mL of 0.5 mg/mL D-luciferin (Research Products In-
ternational, Mt. Prospect, IL). The light emitted was detected using
a luminometer (Turner Designs, Sunnyvale, CA). An ATP standard
curve was generated on the day of each study. ATP levels are re-
ported as nanomoles per 4108 erythrocytes.
2.8. Measurement of free hemoglobin
To exclude the presence of signiﬁcant hemolysis in studies
where the release of ATP was measured, samples were centrifuged
at 500g for 10 min at 4 °C. The presence of free hemoglobin in the
supernatant was determined by light absorption at a wavelength
405 nm [20].
2.9. Determination of the effect of the prostacyclin analog, UT-15C,
on ATP release from healthy human erythrocytes in the presence of
blank liposomes or liposomes containing cilostazol
Washed erythrocytes from healthy humans were diluted to a
20% hematocrit in the physiological buffer described above. Ery-
throcytes were incubated with either blank liposomes or lipo-
somes containing cilostazol (Sigma, St. Louis, MO) for 30 min prior
to the addition of UT-15C (100 nM, United Therapeutics, Research
Triangle Park, NJ). ATP was measured prior to and at 5, 10, and
15 min after addition of UT-15C.
2.10. Determination of ATP release from erythrocytes in response to
exposure to reduced O2 tension in the presence of blank liposomes or
liposomes containing cilostazol
Washed erythrocytes of healthy humans and humans with
DM2 were diluted to a 20% hematocrit in a Ringers buffer con-
taining bicarbonate (in mM; 4.7 KCl, 2.0 CaCl2, 140.5 NaCl, 1.2
MgSO4, 5.5 glucose, 21.4 NaHCO3, 0.5% BSA, pH 7.4 at 37 °C). Cells
were equilibrated for 30 min with a gas mixture containing 15%
O2, 6% CO2, balance N2 (pH¼7.4170.03, pCO2¼3672 mmHg and
pO2¼10775 mmHg; normoxia) in a thin-ﬁlm tonometer (model
237; Instrumentation Laboratory, Bedford, MA) in the presence of
blank liposomes or liposomes containing cilostazol for 20 min. The
gas mixture was then changed to one containing 0% O2, 6% CO2,
balance N2 (pH¼7.4270.02, pCO2¼3872 mmHg and
pO2¼1071 mmHg; low O2 tension). The concentration of ATP
released from erythrocytes was determined during normoxia and
following a 10 min exposure of erythrocytes to low pO2. The pH,
pO2, and pCO2 were determined during exposure to each gas
mixture using a blood gas analyzer (model pHOx; Nova Biomedi-
cal, Waltham, MA).
2.11. Institutional approval
Informed consent was obtained from all subjects. The protocol
for blood removal was approved by the Institutional Review Board
of Saint Louis University. All record keeping was in strict com-
pliance with the Health Insurance Portability and Accountability
Act (HIPAA) regulations.
2.12. Statistical analysis
Statistical signiﬁcance among groups was determined using ananalysis of variance (ANOVA). In the event that the F ratio in-
dicated that a change had occurred, a Fisher's LSD test was per-
formed to identify individual differences. Results are reported as
mean7the standard error (SE).3. Results and discussion
3.1. Preparation and characterization of cilostazol-loaded liposomes
Liposomes were prepared by the hydration of dried lipid ﬁlm
with or without cilostazol followed by extrusion using a previously
published procedure [17]. Several different phospholipids were
used for this study, dioleoylphosphatidylcholine (DOPC), dimir-
istoylphosphatidylcholine (DMPC), dilauroylphosphatidylcholine
(DLPC), and dipalmitoylphosphatidylcholine (DPPC). Throughout
each experiment, each sample was subjected to dynamic light
scattering (DLS) analysis, providing a value for the average size and
the polydispersity index (PDI) of the liposomes in the sample. DLS
data (Fig. 2A) show the formation of liposomes with identical sizes
with and without cilostazol with low PDI. Fig. 2A shows the data
for DMPC; similar results were obtained with all other lipids.
The amount of cilostazol associated with liposomes was de-
termined by high-performance liquid chromatography (HPLC)
following a previously published protocol [21]. During the pre-
paration of liposomes with cilostazol, samples for the HPLC ana-
lysis were collected throughout the preparation steps as men-
tioned in the experimental section. Separation in a size-exclusion
column was done to conﬁrm that cilostazol was associated with
the liposomes. The total quantity of cilostazol found in Samples 1–
3 was the same. Sample 4 (liposomes with cilostazol passed
through a size-exclusion column) showed 87–95% of the amount
found in Sample 3 (liposomes with cilostazol after extrusion and
before size-exclusion column). Considering the high likelihood of
small sample loss during collection from a size-exclusion column,
this ﬁnding indicates that all or nearly all cilostazol used for the
preparation was associated with liposomes. If cilostazol were lo-
cated predominantly in the aqueous phase, it would have been
separated out in the size exclusion separation. Liposomes with the
diameter of approximately 100 nm (Fig. 2A) elute with the void
volume of the column and are readily separated from small mo-
lecules. The inner aqueous volume in this preparation is below 5%
of the total sample volume; therefore, if cilostazol were located
predominantly in the aqueous phase, preparation 4 would have
shown much lower amounts of cilostazol. In further control
measurements, all subsequent fractions eluted from the size ex-
clusion column collected after the liposome fraction did not show
any cilostazol. To demonstrate that cilostazol was effectively de-
livered to erythrocytes using liposome vehicles, ATP release in
response to receptor-mediated activation of the prostacyclin re-
ceptor (IPR) by the prostacyclin analog, UT-15C, was determined in
the absence and presence of cilosatzol-loaded liposomes. The
concentration of UT-15C that was used (100 nM) is insufﬁcient to
stimulate ATP release from healthy human erythrocytes in the
absence of an inhibitor of PDE3.
In addition to measuring UT-15C-induced ATP release, ery-
throcytes were examined under a microscope to evaluate any
potential morphological changes. In initial experiments, UT-15C
was unable to stimulate ATP release in the presence of liposomes
prepared from DOPC. Considering that cilostazol was associated
with these liposomes, we concluded that DOPC liposomes were
not an effective vehicle for cilostazol delivery, most likely due to
ineffective or slow interactions with the membrane of ery-
throcytes. To facilitate fusion of liposomes with erythrocytes, we
tested two saturated phospholipids having the phase transition
temperature below physiological range, DMPC (24 °C) and DLPC
Fig. 2. (A) Size distribution (solid lines) and autocorrelation function (open circles)
of liposomes with and without cilostazol determined by DLS in aqueous solution.
(B) Percent change in ATP release in response to the prostacyclin analog UT-15C
(100 nM) for healthy human erythrocytes (n¼8) in the presence of empty DMPC
liposomes and DMPC liposomes containing cilostazol. Values are means7SE *dif-
ferent from respective control, po0.05. (C and D) LCMS spectra of control ery-
throcytes (C) and liposome-treated erythrocytes (D). These studies demonstrate
that liposomes are a viable vehicle for the delivery of PDE3 inhibitors to human
erythrocytes and that the lipid composition of the liposomes plays an important
role in the successful delivery of cilostazol. In our studies, DMPC liposomes proved
to be the most effective in the delivery of cilostazol to erythrocytes.
Fig. 3. Stability of DMPC liposomes loaded with cilostazol evaluated by DLS mea-
surements. (A) Stacked DLS data acquired daily for one week and (B) average sizes
of liposomes during the one-week period.
S.A. Dergunov et al. / Biochemistry and Biophysics Reports 2 (2015) 137–142140(2 °C). In control experiments we found that DLPC caused sub-
stantial changes in morphology of erythrocytes upon brief in-
cubation. In contrast, DMPC liposomes showed no adverse effect
on erythrocyte morphology. Importantly, incubation of healthy
human erythrocytes with DMPC containing cilostazol signiﬁcantly
increased UT-15C-induced ATP release (Fig. 2B).
We also tested liposomes made of DPPC that had longer hy-
drocarbon chains and a higher phase transition temperature
(41 °C). While we saw no adverse effect of these liposomes on
erythrocyte morphology, we did not observe increases in ATP re-
lease from erythrocytes in response to low O2 tension suggesting
that cilostazol was not delivered effectively to by DPPC liposomes.
These ﬁndings are in agreement with a previously published re-
port on delivery of bilayer-associated pharmaceuticals to ery-
throcytes [22].
LCMS analysis was used to detect the presence of cilostazol and
lipids from liposomes in the membranes of erythrocytes afterincubation. In these experiments, erythrocytes were incubated
with cilostazol-loaded liposomes then washed to remove free li-
posomes and any molecules in the buffer solution. Erythrocytes
were subjected to hypotonic lysis. Hemoglobin and other cyto-
plasmic components were discarded after centrifugation. Lipids
and other hydrophobic components of the pellet were extracted
with chloroform. The extracts were dried to measure the amount
of dry residue, and the solid components were dissolved in me-
thanol and analyzed by mass spectrometry. Fig. 2C shows the mass
spectrum of erythrocytes before incubation with cilostazol-loaded
liposomes.
Lipids of an erythrocyte membrane are typically detected in the
m/z region between 600 and 860. The region below m/z¼600 is
dominated by metabolites of lipids, primarily 1-lysopho-
sphatidylcholines (lyso-PC). An erythrocyte membrane consists of
various lipids that differ in head group type (i.e., phosphati-
dylcholine, phosphatidylserine, phosphatidylethanolamine) and in
their acyl chain length and saturation level [23,24]. These lipids
give rise to a complex signature in the mass spectrum (Fig. 2C).
Lipids from liposomes, however, can easily be detected and iden-
tiﬁed in erythrocyte membranes based on characteristic m/z va-
lues. In electrospray ionization, three different quasi-molecular
ions are created from one molecule due to association of a mole-
cule with Hþ , Naþ , or Kþ , resulting in three different character-
istic peaks in the mass spectrum. DMPC peaks appear atm/z 678.5,
700.5, and 716.5, and cilostazol peaks are visible at m/z 392.1 and
408.1 (Fig. 2D). Stoll et al. [22] showed that the short acyl chain
length lipids have a greater afﬁnity to either incorporate into the
erythrocyte membranes or stick to it compared to the long acyl
chain length lipids. The presence of both DMPC and cilostazol
molecules in the erythrocytes unambiguously conﬁrms successful
delivery of cilostazol to erythrocytes with the help of liposomes.
We examined the stability of liposomes loaded with cilostazol.
DLS data (Fig. 3) show no change in the average size and size
distribution of liposomes during one week of storage at 4 °C. Fu-
sion of liposomes, a major reason for their instability, would
Fig. 4. ATP release from healthy human (n¼7) (A) and DM2 erythrocytes (n¼6)
(B) incubated with blank liposomes or liposomes containing cilostazol during
normoxia and following exposure to reduced oxygen tension. Values are mean-
s7SE. *; different from respective normoxia, po0.05: †different from respective
normoxia, po0.01: NS; not different.
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of the size distribution. Lack of change in these parameters (Fig. 3)
indicates the stability of liposomes. Experiments on the delivery of
cilostazol to erythrocytes described below were performed at
different times following the preparation of the liposomes loaded
with cilostazol, between several hours and one week with no
measurable difference. The stability of cilostazol-loaded DMPC
liposomes is similar to the stability of blank DMPC liposomes
reported previously [21].
3.2. Impact of liposome-delivered cilostazol on ATP release from
healthy Human and DM2 erythrocytes
Previous studies demonstrated that incubation of DM2 ery-
throcytes with cilostazol restores ATP release in response to low
O2 tension [1]. To evaluate the ability of cilostazol-containing li-
posomes to similarly rescue low O2-induced ATP release from DM2
erythrocytes, cells from both healthy humans and humans with
DM2 were incubated with liposomes prepared from DMPC with or
without cilostazol.
First, in a set of control experiments, we determined that
healthy erythrocytes are not adversely affected by DMPC lipo-
somes and that they respond to liposome-delivered cilostazol.
When incubated with liposomes that did not contain cilostazol,
healthy human erythrocytes released ATP when exposed to re-
duced O2 tension (Fig. 4A). The release of ATP was the same as
previously observed for healthy erythrocytes in the absence of any
treatment. Importantly, these cells also released ATP in response to
this stimulus when incubated with liposomes containing cilosta-
zol. These ﬁndings illustrate that DMPC liposomes loaded with the
PDE3 inhibitor had no adverse effect on healthy human ery-
throcytes. As mentioned above, the effect of liposomes on ery-
throcytes is lipid-speciﬁc.
DM2 erythrocytes did not release ATP when exposed to re-
duced O2 in the presence of blank liposomes (Fig. 4B). This out-
come is identical to the normal behavior of DM2 erythrocytes inreduced O2 environment [1]. When incubated with liposomes
containing cilostazol, this stimulus resulted in ATP release that
was not different from the amount released from healthy human
erythrocytes under the same conditions (Fig. 4A and B). This
ﬁnding is similar to previously published results demonstrating
that incubation of DM2 erythrocytes with cilostazol in solution.
That study demonstrated that incubation of DM2 erythrocyte with
cilostazol (100 mM) resulted in a 105745% increases in ATP re-
lease when the cells were exposed to low oxygen tension [3]. Here
we show that exposure of DM2 erythrocytes to liposomes loaded
with cilostazol also rescues low oxygen-induced ATP release and
that the increases is 107720% (po0.05, Fig. 4). Thus, the results
presented here establish that (1) liposome-mediated delivery of
PDE3 inhibitors to erythrocytes of humans with DM2 restores the
physiological response to exposure to low O2 and (2) the magni-
tude of the rescue is similar to that observed when cilostazol is
incubated directly with these cells [3]. Combined with experi-
ments showing retention of cilostazol in liposomes, these studies
conﬁrm successful liposomal delivery of cilostazol and demon-
strate the feasibility of achieving targeted delivery of PDE in-
hibitors to erythrocytes.
In summary, we demonstrated the successful delivery of ci-
lostazol, a PDE3 inhibitor, to erythrocytes, using liposomes as ve-
hicles. The efﬁciency of the delivery of cilostazol to erythrocytes is
sensitive to the liposome formulation. Using DMPC liposomes, we
were able to achieve quantitative delivery of cilostazol. Im-
portantly, liposome-delivered cilostazol rescued the ability of er-
ythrocytes of humans with DM2 to release ATP in response to low
O2. Targeting of erythrocytes for the delivery of PDE3 inhibitors
could have signiﬁcant translational importance in the treatment of
DM2.
Traditionally, formulations of liposomes for drug delivery were
designed to prolong the circulation time of drugs and to minimize
their interactions with blood components. Here we exploited the
potential for interaction of liposomes with erythrocytes to our
advantage. Systemic effects of PDE3 inhibitors have limited their
usefulness in DM2 [8]. The targeted delivery of these drugs to
erythrocytes would minimize their unwanted side effects and re-
presents a novel approach to the treatment of the vascular disease
and delayed wound healing associated with DM2.Acknowledgments
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